8.32

1.59% 0.13

After Hours: 8.33 0.010 +0.12%

Amneal Pharmaceuticals Inc (AMRX)

Overview News Price History Option Chain Discussions Forecast

Amneal Pharmaceuticals Inc stock is traded at $8.32, with a volume of 1.02M. It is up +1.59% in the last 24 hours and down -3.93% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Previous Close:

$8.19

Open:

$8.11

24h Volume:

1.02M

Relative Volume:

0.76

Market Cap:

$2.53B

Revenue:

$2.50B

Net Income/Loss:

$-168.69M

P/E Ratio:

-416.00

EPS:

-0.02

Net Cash Flow:

$124.24M

1W Performance:

-2.35%

1M Performance:

-3.93%

6M Performance:

+37.29%

1Y Performance:

+97.16%

1-Day Range:

$8.01

$8.34

1-Week Range:

$8.01

$8.52

52-Week Range:

$3.36

$8.905

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name

Amneal Pharmaceuticals Inc

Sector

Healthcare (1190)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

908-947-3120

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater

Employee

5,210

Twitter

@amnealpharma

Next Earnings Date

2024-08-09

Latest SEC Filings

AMRX's Discussions on Twitter

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Mar-08-21	Upgrade	Goldman	Sell → Buy
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy
Jul-27-20	Initiated	Goldman	Sell
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy
Mar-20-19	Initiated	SunTrust	Buy
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Dec-14-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-16-18	Downgrade	SunTrust	Buy → Hold
Aug-13-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jul-23-18	Initiated	Morgan Stanley	Overweight
Jun-22-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

Sep 29, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat

Sep 29, 2024

Renaissance Technologies LLC Raises Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Sep 29, 2024

Sep 27, 2024

Wall Street SWOT: Amneal Pharmaceuticals stock rides wave of growth and innovation - Investing.com

Sep 27, 2024

Pharmaceutical company sues Colorado over epinephrine price-cap law - MSN

Sep 27, 2024

Sep 25, 2024

Pharmaceutical company sues Colorado over epinephrine price-cap law - Yahoo News

Sep 25, 2024

Pharmaceutical company sues Colorado over epinephrine price-cap law - AOL

Sep 25, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stake Lifted by BlackBarn Capital Partners LP - MarketBeat

Sep 25, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Position Lifted by BlackBarn Capital Partners LP - Defense World

Sep 25, 2024

Sep 24, 2024

Investors in Amneal Pharmaceuticals (NASDAQ:AMRX) have seen splendid returns of 194% over the past five years - Simply Wall St

Sep 24, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Victory Capital Management Inc. - MarketBeat

Sep 24, 2024

Sep 23, 2024

Amneal launches Parkinson's drug Crexont in US pharmacies - Investing.com

Sep 23, 2024

Amneal Latest Generic EpiPen Maker To Fight Colo. Law - Law360

Sep 23, 2024

Amneal launches Parkinson's drug Crexont in US pharmacies By Investing.com - Investing.com Canada

Sep 23, 2024

Amneal asks court to block Colorado's free allergy pen program - Reuters

Sep 23, 2024

Amneal launches Parkinson's drug Crexont in US pharmacies - Investing.com India

Sep 23, 2024

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease - BioSpace

Sep 23, 2024

Amneal launches Parkinson's drug Crexont in US pharmacies By Investing.com - Investing.com UK

Sep 23, 2024

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease - StockTitan

Sep 23, 2024

Sep 21, 2024

Rubric Capital Management LP Increases Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Sep 21, 2024

Sep 20, 2024

Why Nike Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga

Sep 20, 2024

Nothing is Better Than Amneal Pharmaceuticals Inc (AMRX) stock at the moment - SETE News

Sep 19, 2024

Bernstein cuts Nike stock target, maintains outperform on bearish outlook By Investing.com - Investing.com Australia

Sep 19, 2024

Sep 18, 2024